Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in nonfunctioning pituitary adenomas: A high throughput tma, immunohistochemical study

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 5, 2012, Pages 1745-1751

  Ramírez, Claudia ^a   Cheng, Sonia ^b   Vargas, Guadalupe ^a   Asa, Sylvia L ^b   Ezzat, Shereen ^b   González, Baldomero ^a   Cabrera, Lourdes ^c   Guinto, Gerardo ^c   Mercado, Moisés ^a  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c HOSPITAL DE ESPECIALIDADES   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; FIBROBLAST GROWTH FACTOR RECEPTOR 4; KI 67 ANTIGEN; SECURIN; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 5;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER SURGERY; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; ENZYME ACTIVITY; FEMALE; GONADOTROPIN SECRETING CELL; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NONFUNCTIONING PITUITARY ADENOMA; NULL CELL ADENOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TERTIARY HEALTH CARE; TISSUE MICROARRAY; TUMOR RECURRENCE; TUMOR VOLUME;

ADENOMA; ADULT; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PITUITARY NEOPLASMS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 4; RECEPTORS, SOMATOSTATIN; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84860703212     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-3163     Document Type: Article

References (40)

1. Monson JP 2000 The epidemiology of endocrine tumours. Endocr Relat Cancer 7:29-36
2. Jaffe CA 2006 Clinically non-functioning pituitary adenoma. Pituitary 9:317-321
3. Molitch ME 2008 Nonfunctioning pituitary tumors and pituitary incidentalomas. Endocrinol Metab Clin North Am 37:151-171, xi
4. Asa SL 2011 AFIP atlas of tumor pathology. Series 4. Fascicle 15. London: STM Books
5. De Lellis RA, Lloyd RV, Heitz PU, Eng C 2004 Pathology and genetics of tumors of endocrine organs. World Health Organization classification of tumors. Lyon, France: IARC Press; 9-45
6. Al-Shraim M, Asa SL 2006 The 2004 World Health Organization classification of pituitary tumors: what is new? Acta Neuropathol (Berl) 111:1-7
7. Jane Jr JA, Laws Jr ER 2003 The management of non-functioning pituitary adenomas. Neurol India 51:461-465
8. Dekkers OM, Pereira AM, Romijn JA 2008 Treatment and follow-up of clinically nonfunctioning pituitary macroadenomas. J Clin Endocrinol Metab 93:3717-3726
9. Di Chiro G, Nelson KB 1962 The volume of the sella turcica. Am J Roentgenol Radium Ther Nucl Med 87:989-1008
10. Gerdes J, Li L, Schlueter C, Duchrow M, Wohlenberg C, Gerlach C, Stahmer I, Kloth S, Brandt E, Flad HD 1991 Immunobiochemical and molecular biologic characterization of the cell proliferati on associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol 138:867-873
11. Burger PC, Shibata T, Kleihues P 1986 The use of the monoclonal antibody Ki-67 in the identification of proliferating cells: application to surgical neuropathology. Am J Surg Pathol 10:611-617
12. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO 2009 Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101:736-750
13. Kiviniemi M, Sauroja I, Rajamäki A, Punnonen K, Söderström KO, Salminen E 2000 Cell cycle regulators p27 and pRB in lymphomas-correlation with histology and proliferative activity. Br J Cancer 83:1161-1167
14. Gejman R, Swearingen B, Hedley-Whyte ET 2008 Role of Ki-67 proliferation index and p53 expression in predicting progression of pituitary adenomas. Hum Pathol 39:758-766
15. Noh TW, Jeong HJ, Lee MK, Kim TS, Kim SH, Lee EJ 2009 Predicting recurrence of nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 94:4406-4413
16. Widhalm G, Wolfsberger S, Preusser M, Fischer I, Woehrer A, Wunderer J, Hainfellner JA, Knosp E 2009 Residual nonfunctioning pituitary adenomas: prognostic value of MIB-1 labeling index for tumor progression. J Neurosurg 111:563-571
17. Losa M, Franzin A, Mangili F, Terreni MR, Barzaghi R, Veglia F, Mortini P, Giovanelli M 2000 Proliferation index of non functioning pituitary adenomas: correlations with clinical characteristics and long-term follow-up results. Neurosurgery 47:1313-1318; discussion 1318-1319
18. Dubois S, Guyétant S, Menei P, Rodien P, Illouz F, Vielle B, Rohmer V 2007 Relevance of Ki-67 and prognostic factors for recurrence/ progression of gonadotropic adenomas after first surgery. Eur J Endocrinol 157:141-147
19. Chacko G, Chacko AG, Kovacs K, Scheithauer BW, Mani S, Muliyil JP, Seshadri MS 2010 The clinical significance of MIB-1 labeling index in pituitary adenomas. Pituitary 13:337-344
20. Pei L, Melmed S 1997 Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Mol Endocrinol 11:433-441
21. Zou H, McGarry TJ, Bernal T, Kirschner MW 1999 Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. Science 285:418-422
22. Vlotides G, Eigler T, Melmed S 2007 Pituitary tumor-transforming gene: physiology and implications for tumorigenesis. Endocr Rev 28:165-186
23. McCabe CJ, Khaira JS, Boelaert K, Heaney AP, Tannahill LA, Hussain S, Mitchell R, Olliff J, Sheppard MC, Franklyn JA, Gittoes NJ 2003 Expression of pituitary tumour transforming gene (PTTG) and fibroblast growth factor-2 (FGF-2) in human pituitary adenomas: relationships to clinical tumour behaviour. Clin Endocrinol (Oxf) 58:141-150
24. Zhang X, Horwitz GA, Heaney AP, Nakashima M, Prezant TR, Bronstein MD, Melmed S 1999 Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. J Clin Endocrinol Metab 84:761-767
25. Filippella M, Galland F, Kujas M, Young J, Faggiano A, Lombardi G, Colao A, Meduri G, Chanson P 2006 Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study. Clin Endocrinol (Oxf) 65:536-543
26. Sáez C, Japón MA, Ramos-Morales F, Romero F, Segura DI, Tortolero M, Pintor-Toro JA 1999 hpttg is over-expressed in pituitary adenomas and other primary epithelial neoplasias. Oncogene 18:5473-5476
27. Givol D, Yayon A 1992 Complexity of FGF receptors: genetic basis for structural diversity and functional specificity. FASEB J 6:3362-3369
28. Abbass SA, Asa SL, Ezzat S 1997 Altered expression of fibroblast growth factor receptors in human pituitary adenomas. J Clin Endocrinol Metab 82:1160-1166
29. Ezzat S, Zheng L, Zhu XF, Wu GE, Asa SL 2002 Targeted expression of a human pituitary tumor-derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis. J Clin Invest 109:69-78
30. Qian ZR, Sano T, Asa SL, Yamada S, Horiguchi H, Tashiro T, Li CC, Hirokawa M, Kovacs K, Ezzat S 2004 Cytoplasmic expression offibroblast growth factor receptor-4inhuman pituitary adenomas: relation to tumor type, size, proliferation, and invasiveness. J Clin Endocrinol Metab 89:1904-1911
31. Jaquet P, Gunz G, Saveanu A, Dufour H, Taylor J, Dong J, Kim S, Moreau JP, Enjalbert A, Culler MD 2005 Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classifiedas partially responsive tosomatostatin analog therapy. Eur J Endocrinol 153:135-141
32. Bevan JS 2005 Clinical review: the antitumoral effects of somatostat in analog therapy in acromegaly. J Clin Endocrinol Metab 90:1856-1863
33. Plöckinger U, Albrecht S, Mawrin C, Saeger W, Buchfelder M, Petersenn S, Schulz S 2008 Selective loss of somatostatin receptor 2 in octreotide-resistant growth hormone-secreting adenomas. J Clin Endocrinol Metab 93:1203-1210
34. Greenman Y, Melmed S 1994 Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence of preferential SSTR5 expression in the mammosomatotroph lineage. J Clin Endocrinol Metab 79:724-729
35. Nielsen S, Mellemkjaer S, Rasmussen LM, Ledet T, Olsen N, Bojsen-Møller M, Astrup J, Weeke J, Jørgensen JO 2001 Expression of somatostatin receptors on human pituitary adenomasin vivo and ex vivo. J Endocrinol Invest 24:430-437
36. Taboada GF, Luque RM, Bastos W, Guimarães RF, Marcondes JB, Chimelli LM, Fontes R, Mata PJ, Filho PN, Carvalho DP, Kineman RD, Gadelha MR 2007 Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas. Eur J Endocrinol 156:65-74
37. Zatelli MC, Piccin D, Vignali C, Tagliati F, Ambrosio MR, Bondanelli M, Cimino V, Bianchi A, Schmid HA, Scanarini M, Pontecorvi A, De Marinis L, Maira G, degli Uberti EC 2007 Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion. Endocr Relat Cancer 14:91-102
38. Tateno T, Kato M, Tani Y, Oyama K, Yamada S, Hirata Y 2009 Differential expression of somatostatin and dopamine receptor subtype genes in adrenocorticotropin (ACTH)-secreting pituitary tumors and silent corticotroph adenomas. Endocr J 56:579-584
39. Pawlikowski M, Pisarek H, Kunert-Radek J, Radek A 2003 Immunohistochemical detection of somatostatin receptor subtypes in "clinically nonfunctioning" pituitary adenomas. Endocr Pathol 14:231-238
40. Pisarek H, Pawlikowski M, Kunert-Radek J, Radek M 2009 Expression of somatostatin receptor subtypes in human pituitary adenomas: immunohistochemical studies. Endokrynol Pol 60:240-251